You searched for "Outlook"

768 results found

Management of ocular surface disease

This is a retrospective study of patients with ocular surface disease (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease), active...

Preterm birth and refractive error in an Indian infant population

This study was undertaken to identify and compare the changes in refractive outcome in infants with and without retinopathy of prematurity (ROP), to inform incidence of refractive error. This was a prospective study of 300 consecutive premature infants with birth...

Management of strabismus due to orbital wall fractures

The authors present a retrospective single centre review of patients with strabismus due to orbital wall fractures with regard to their clinical presentation and outcomes. The study included 347 patients; 87% male and mean age of 32.42 ±12.9 years. Ten...

Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases

This is a retrospective study of patients with ocular surface inflammatory diseases (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease),...

Symfony and vivity: comparing two EDOF IOLs

This prospective, randomised, double-masked, single-surgeon study compared the visual outcome between two commonly used extended depth of focus (EDOF) lenses, the Tecnis Symfony IOL (Johnson & Johnson Vision) and the Acrysof IQ Vivity IOL (Alcon Laboratories, Inc.). Sixty-nine patients underwent...

Patients prefer vision from lasik than from smile in a contralateral-eye trial

This prospective, randomised, single surgeon, contralateral-eye clinical trial compared the results in myopic patients undergoing wavefront-guided femtosecond laser in situ keratomileusis (LASIK) in one eye and small-incision lenticule extraction (SMILE) in the fellow eye. The patient-reported outcomes with laser in...

Narrative review of opsoclonus myoclonus ataxia syndrome following COVID-19

Opsoclonus myoclonus syndrome (OMS) / opsoclonus myoclonus ataxia syndrome (OMAS) is a rare central nervous system manifestation of COVID-19, but an increasing number of articles have reported patients in whom COVID-19 was complicated by OMS / OMAS. This narrative review...

Outcomes of reinjection of Ranibizumab for reactivation of retinopathy of prematurity

The authors present their data from Egypt assessing the effects of Ranibizumab reinjection for neonates with retinopathy of prematurity (ROP). Doses given were 0.25mg/0.025mL. They screened 2318 infants with 115 (5%) of infants with a mean post menstrual age (PMA)...

Multidrug-resistant keratitis: challenging yet manageable

This is a retrospective review of all patients’ records from a tertiary referral centre in India from January 2018 to December 2019, who had corneal scrapings for direct smear and culture sensitivity. Those cases where the organisms were diagnosed to...

Using a tumour registry to investigate optic nerve gliomas

This study is a retrospective comparative analysis. Patients with optic nerve glioma and pilocytic astrocytoma were identified through the Surveillance, Epidemiology and End Results (SEER) cancer registry covering a 42-year period using standardised codes. The following data was extracted: basic...

Tutopatch® in surgical management of third nerve palsy

his study evaluates the benefit of using Tutopatch® to elongate the extraocular muscles in patients with third nerve palsy who have residual strabismus after unsuccessful surgery and no other surgical options considered to be appropriate. The study included nine patients...

Ophthalmic presentations and outcomes in Erdheim-Chester disease

This is a comprehensive article describing clinical manifestations and pathogenesis of Erdheim-Chester disease (ECD) followed by a literature review of the available treatments. The authors look to compare historical treatment (HT) with vemurafenib, a BRAF inhibitor. ECD is a non-Langerhans...